Goldman Sachs resumes AbCellera stock coverage with neutral rating
Goldman Sachs resumed coverage of AbCellera Biologics (NASDAQ:ABCL) with a Neutral rating and a $13.00 price target. The company reported Q2 revenue of $4.1M, missing estimates, but announced successful Phase 2 trial results for ABCL635, leading Truist to raise its price target to $30. AbCellera has a strong cash position and recently launched a $200M stock offering.
How this was made
The 30-second read
Why it matters
Coverage resumption and Phase 2 success provide fresh catalysts that could influence short‑term trading.
Market read
New analyst actions and trial data create a modest trading opportunity for ABCL.
What to watch
Potential dilution from the $200 M public offering could offset trial optimism.
Background
AbCellera is a clinical‑stage biotech focused on antibody discovery, recently shifting toward internal pipeline development.
Ticker impact
Goldman Sachs resumed coverage on AbCellera with a neutral rating and $13 price target, and the company announced positive Phase 2 results for ABCL635.
Potential modest upside toward the $13 target if trial data spurs investor interest.
Coverage change and new data are fresh information, but the stock already trades near its 52‑week high, limiting upside.
Market effects
Positive biotech trial results may boost confidence in antibody discovery platforms.
North American biotech sector may see modest gains.
Limited to biotech investors; no broad market effect.
Counterpoint
The stock is already near its 52‑week high; the neutral rating suggests limited upside.
Key entities
- AnalystGoldman Sachs
Resumed coverage with neutral rating and $13 price target.
- AnalystTruist Securities
Raised price target to $30 after Phase 2 results.
